Pralatrexate Injection
Product Images NDC 65219-552

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pralatrexate (NDC 65219-552). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Pra09 0000 01)

FDA Label Image

Fresenius Kabi Logo (Pra09 0000 02)

FDA Label Image

Fresenius Kabi Logo (Pra09 0000 03)

FDA Label Image

Principal Display Panel – Pralatrexate Injection 20 mg/ml – Carton (Pra09 0000 04)

Pralatrexate Injection is a medication for intravenous use only. The vial contains 20 mg/mL of Pralatrexate and must be protected from light. It should be refrigerated at 2 to 8° C and not diluted. The recommended dosage is administered as an intravenous push over 3-5 minutes. This medication is for single-dose only and must be stored in the carton until use. The package insert includes further details on administration. Pralatrexate is manufactured for Fresenius-Kabi in Germany.*

FDA Label Image

Principal Display Panel – Pralatrexate Injection 20 mg/ml – Vial Label (Pra09 0000 05)

This is a product label of Pralatrexate Injection, with NDC number 65219-550-01, manufactured for Fresenius Kabi in Lake Zurich Illinois. No other information apart from the manufacturing location is available.*

FDA Label Image

Principal Display Panel – Pralatrexate Injection 40 mg/2 mL – Carton (Pra09 0000 06)

This is a description of Pralatrexate Injection, a medication that is intended for intravenous use. Each vial contains a sterile solution of 40 mg/2 mL (20mg/mL) of Pralatrexate and is designed to be used as a single dose only. It contains sodium chloride to produce isotonic solution, and it should not be diluted. The recommended dosage is to be administered as an intravenous push over 3-5 minutes. It is important to store the medication in its carton until use and to protect it from light. This medication is manufactured by Fresenius Kabi in Germany.*

FDA Label Image

Principal Display Panel – Pralatrexate Injection 40 mg/2 mL – Vial Label (Pra09 0000 07)

This is a description of a medication labeled as Pralatrexate. It is an injection solution with a concentration of 20mg/mL and a total volume of 2mL, containing 40mg of Pralatrexate. The medication is available only through a prescription (Rx only) and has an NDC code of 65219-552-02. The manufacturer of this medication is Fresenius Kabi and it is manufactured in Lake Zurich, IL.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.